New Pharmaceuticals market report from TechNavio: "Global Hypercholesterolemia Market 2014-2018"

Boston, MA -- (SBWire) -- 07/10/2014 --Hypercholesterolemia is defined as a condition characterized by abnormally high levels of total cholesterol and LDL cholesterol in the blood. High cholesterol levels, in turn, can lead to cardiovascular diseases such as atherosclerosis and stroke. The normal physiological range of total blood cholesterol is 140-200 mg/dL. However, blood cholesterol consists of various individual components such as LDL cholesterol and HDL cholesterol. While LDL delivers cholesterol to the body, HDL removes cholesterol from cells by reverse cholesterol transport to the liver. Owing to their distinct roles, these components are separately taken into account to determine the dyslipidemic status of an individual. The inheritable form of hypercholesterolemia, characterized by elevated total cholesterol and LDL cholesterol levels, is known as familial hypercholesterolemia. When the condition is inherited due to the presence of one abnormal copy of the LDL receptor gene, it is known as heterozygous familial hypercholesterolemia. The presence of abnormal copies of both the LDL receptor alleles leads to homozygous familial hypercholesterolemia.

View Full Report Details and Table of Contents

TechNavio's analysts forecast the Global Hypercholesterolemia market will grow at a CAGR of 3.81 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Hypercholesterolemia market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various hypercholesterolemia management drugs that are available in the market which includes statins and other serum lipid lowering drugs. The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Global Hypercholesterolemia market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Hypercholesterolemia Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hypercholesterolemia market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

- Americas
- EMEA
- APAC

Key Vendors

- AbbVie Inc.
- Astrazeneca PLC
- Merck & Co., Inc.
- Pfizer Inc.

Other Prominent Vendors

- Aegerion Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc.
- Amgen Inc.
- AtheroNova Inc.
- Biospherics.net Incorporated
- Bristol-Myers Squibb Company
- Catabasis Pharmaceuticals Inc.
- Cerenis Therapeutics, SA
- CymaBay Therapeutics, Inc.
- Daiichi Sankyo Inc.
- Eli Lilly and Company
- Esperion Therapeutics Inc.
- Glaxosmithkline plc
- Kadmon Pharmaceuticals LLC
- Kowa Pharmaceuticals America Inc.
- Laboratoires SMB S.A.
- Madrigal Pharmaceuticals Inc.
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- REGENX BioSciences, LLC
- Santaris Pharma A/S
- Serometrix LLC
- Shionogi Pharma Inc.
- Spherix Incorporated
- Sun Pharma USA
- Tekmira Pharmaceuticals Corp.

Key Market Driver

- Increase in the Incidence and Prevalence of Cardiovascular Diseases.
- For a full, detailed list, view our report.

Key Market Challenge

- Increase in Generic Erosion.
- For a full, detailed list, view our report.

Key Market Trend

- Fierce Market Competition.
- For a full, detailed list, view our report.

Key Questions Answered in this Report

- What will the market size be in 2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: AbbVie Inc., Astrazeneca PLC, Merck & Co. Inc., Pfizer Inc., Aegerion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., AtheroNova Inc., Biospherics.net Incorporated, Bristol-Myers Squibb Company, Catabasis Pharmaceuticals Inc., Cerenis Therapeutics, SA, CymaBay Therapeutics Inc., Daiichi Sankyo Inc., Eli Lilly and Company, Esperion Therapeutics Inc., Glaxosmithkline plc, Kadmon Pharmaceuticals LLC, Kowa Pharmaceuticals America Inc., Laboratoires SMB S.A., Madrigal Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc., REGENX BioSciences LLC, Santaris Pharma A/S, Serometrix LLC, Shionogi Pharma Inc., Spherix Incorporated, Sun Pharma USA, Tekmira Pharmaceuticals Corp.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Hypercholesterolemia Global Clinical Trials Review, H1, 2014
- Hypercholesterolemia - Pipeline Review, H1 2014
- Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2014
- Hypercholesterolemia - Pipeline Review, H2 2013
- Genomics Market by Products - [Instruments (NGS platform, Microarray, RT-PCR), Consumables (Genechips, Reagents for DNA Extraction & Purification, Sequencing)], Services (Sequencing & Microarray Services, and Software) - Global Forecast to 2018
- Partnerships, Licensing, Investments and M&A Deals and Trends for July 2013 in Pharmaceuticals
- Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals
- Partnerships, Licensing, Investments and M&A Deals and Trends for June 2013 in Pharmaceuticals
- Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2013
- Pharmaceuticals Monthly Deals Analysis: October 2013 - Partnerships, Licensing, Investments and M&A Trends